Ability of BM CD4⁺ and CD8⁺ T cells to mediate anti-BCL₁ tumor activity.

Graded numbers of sorted C57BL/6 BM CD4⁺, CD8⁺, or CD4⁺/CD8⁺ T cells were added to a constant number of C57BL/6 Rag-2^−/− BM cells (1.5 × 10⁶) and 60 BALB/c BCL₁cells and injected intravenously into lethally irradiated BALB/c recipients. Survival over a 100-day observation period is shown for groups of 10 mice. Data are combined from 2 replicate experiments. (A) Graded numbers of BM CD8⁺ T cells. (B) BM NK1.1⁺ or NK1.1⁻ CD8⁺ T cells. (C) C57BL/6 BM CD4⁺ T cells or BM CD8⁺ T cells from C57BL/6xBALB/c F1 mice. (D) Graded numbers of BM CD4⁺/CD8⁺ T cells.